The frequency of coinfection with Borrelia burgdorferi and either Anaplasma phagocytophila or Babesia microti among patients with erythema migrans, the initial skin lesion of Lyme disease, was assessed in 2 mainland locations in Rhode Island and Connecticut in a 4-year prospective study. Of the 93 patients with culture-proven erythema migrans, 2 (2%) patients had coinfection with A. phagocytophila and 2 (2%) had coinfection with B. microti. We concluded that the frequency of coinfection with these agents was low among patients with erythema migrans in the study areas.
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In the northeastern and upper midwestern United States, Lyme disease is caused by a spirochete, Borrelia burgdorferi, that is primarily transmitted by nymphal Ixodes scapularis ticks [1] . In ∼80% of cases, Lyme disease begins in the summer with an expanding skin lesion, erythema migrans, that may be accompanied by systemic symptoms, including malaise, fatigue, fever, headache, neck stiffness, arthralgias, or myalgias. In ∼15% of cases, infected individuals may present with systemic symptoms without erythema migrans.
Nymphal I. scapularis ticks may transmit other infectious agents, such as Babesia microti (an RBC parasite) or Anaplasma phagocytophila (formerly referred to as "the agent of human granulocytic ehrlichiosis") [2] . As with B. burgdorferi infection, infection with these other tickborne agents may cause nonspecific systemic symptoms, and coinfected patients may have more severe or persistent illness [3, 4] .
Previous reports of the frequency of coinfection among patients with erythema migrans have been quite variable [3] [4] [5] [6] [7] [8] .
In the current prospective study, which was conducted over a 4-year period, we used strict criteria to assess coinfection among patients with erythema migrans who resided in mainland locations in Rhode Island or Connecticut where Lyme disease is highly endemic.
Patients and methods. From 1998 through 2001, a total of 115 patients with erythema migrans were recruited at 2 field sites, one in East Lyme, Connecticut (by V.K.S.), and the other in Wakefield, Rhode Island (by N.D.). The study was approved by the Human Investigations Committee at New England Medical Center (Boston, MA), and informed consent was obtained from all patients. The patients met the Centers for Disease Control and Prevention (Atlanta, GA) criteria that are used for Lyme disease surveillance [1] . All patients had "erythema migrans," which was defined as an expanding, annular skin lesion (diameter, у5 cm) with or without partial central clearing.
After informed consent was obtained, physicians performed a clinical assessment of signs and symptoms of the infection by means of a standardized questionnaire. A 1.5-mm punch biopsy of the skin at the leading edge of erythema migrans skin lesions was performed for culture of B. burgdorferi, and an EDTA-anticoagulated blood sample was obtained for detection of A. phagocytophila and B. microti by PCR. For detection of all 3 infectious agents by serological testing, an acute-phase serum sample was obtained. The samples were sent overnight to New England Medical Center for analysis. At the conclusion of antibiotic treatment ∼3 weeks later, a convalescent-phase serum sample was obtained.
Upon receipt at the laboratory, skin biopsy samples were cultured for B. burgdorferi in modified Barbour-StoennerKelly II medium (BSK-H; Sigma), and serological testing for B. burgdorferi was performed using a 2-test approach (ELISA and Western blot) [1] . B. burgdorferi was cultured from erythema migrans skin lesions of 93 (81%) of 115 patients who were seen at the field study sites. To be certain of the diagnosis of Lyme disease, testing for coinfecting agents was done only for these 93 patients.
For tests of coinfection, we used an A. phagocytophilainfected HL60 leukemia cell line and an uninfected HL60 leukemia cell line (cell lines were kindly provided by Dr. Jesse Goodman, University of Minnesota, Minneapolis, MN), and citrated blood samples obtained from female golden hamsters infected with B. microti (blood samples were kindly provided by Dr. Sam Telford, Harvard School of Public Health, Boston, MA). For PCR testing, DNA was extracted from 100-mL samples of blood from patients with a commercial kit (Isoquick; Orca Research). After extraction, the DNA pellet was resuspended in 50 mL of H 2 O. For detection of A. phagocytophila DNA, a specific 16S rRNA gene sequence was targeted, and amplification was performed according to the method described by Pancholi et al. [9] . The positive control was DNA extracted from A. phagocytophila-infected HL60 cells, and the negative control was uninfected HL60 cells. For the detection of B. microti DNA, an ss-rRNA gene of B. microti was targeted, and amplification was performed as described by Persing et al. [10] . The positive control was DNA extracted from B. microtiinfected human blood. For both infectious agents, a water control was included. Amplification products were visualized on ethidium bromide-stained 1.8% agarose gels. For serological testing, 12-well indirect immunofluorescence assay slides (Cel-Line; Erie Scientific) were prepared with A. phagocytophila antigens or B. microti antigens, as described elsewhere [11, 12] . The slides were screened by indirect immunofluorescence at a 1:80 dilution for the detection of IgM or IgG anti-A. phagocytophila antibodies and at a 1:64 dilution for the detection of IgM or IgG anti-B. microti antibodies [11, 12] . For both agents, samples that yielded positive results at the screening dilutions were titered to the end point, and samples from patients with positive PCR results that yielded negative results at screening dilutions were tested at lower dilutions. The end point was defined as the highest titer in which all organisms still fluoresced dimly. In addition, for standardization and control of the procedure, the same high-titer positive control, low-titer negative control, and blank well contents (i.e., PBS) were included with each test.
Results. From 1998 through 2001, at 2 mainland study sites in southern Rhode Island and southeastern Connecticut, 93 patients had erythema migrans skin lesions from which B. burgdorferi was cultured. Of these 93 patients, 2 (2%) had coinfection with A. phagocytophila and 2 (2%) had coinfection with B. microti (table 1). All 93 patients experienced onset of erythema migrans from May through September, and 58 patients (62%), including the 4 who were coinfected with either A. phagocytophila or B. microti, experienced onset of symptoms in June or July. The yearly incidence of coinfection with either A. phagocytophila or B. microti at the 2 study sites ranged from 0 to 9 cases per 100 patients with erythema migrans. The overall frequency of coinfection during the 4-year prospective study was 4 cases per 100 patients.
The 4 coinfected patients for whom cultures of biopsy samples were positive for B. burgdorferi also had positive IgM responses to the spirochete. In addition, of the 2 patients with A. phagocytophila coinfection, 1 had positive PCR results for A. phagocytophila DNA in blood, and 1 had a positive IgG response to this agent. Of the 2 patients with B. microti coinfection, one had a positive PCR result for B. microti DNA in blood and a positive IgG response to this organism and the other had IgG seroconversion to the organism. One additional patient had an IgG antibody response to A. phagocytophila of 1:160 in both acute-and convalescent-phase serum samples. However, this patient was not included in the case series, because coinfection could not be distinguished from sequential infection. For both agents, PCR results were replicable on successive testing. Thus, for the 4 coinfected patients, B. burgdorferi infection was documented by culture, and anaplasmosis or babesiosis was documented by PCR, IgG seroconversion, or both.
Both patients with A. phagocytophila coinfection and one patient with B. microti coinfection had 8-11 symptoms associated with erythema migrans, including malaise, fatigue, fever, chills, headache, neck stiffness, arthralgias, myalgias, abdominal pain, or anorexia (table 2) . However, the remaining patient who was coinfected with B. microti had no associated symptoms. The 4 coinfected patients were treated with doxycycline, and 3 experienced resolution of illness within a median duration of 7 days. The fourth patient, who was coinfected with A. phagocytophila, had persistent fatigue. When the clinical pictures of the 89 patients with B. burgdorferi infection alone were compared with those of the 4 coinfected patients, the coinfected patients tended to have more symptoms, but their clinical pictures lacked distinctive characteristics. Discussion. In this 4-year prospective study of 93 patients with culture-proven erythema migrans, 2 patients had coinfection with A. phagocytophila and 2 had coinfection with B. microti. In an initial serosurvey in which testing was performed by indirect immunofluorescence, 20 (67%) of 30 Long Island residents with antibody to B. burgdorferi also had B. microtireactive serum samples [5] . In a serosurvey of Connecticut residents performed by ELISA (with a polyvalent conjugate), 3 (7.5%) of 40 patients who had elevated antibody titers to B. burgdorferi also had antibodies to B. microti, and 4 patients (10%) had antibodies to Ehrlichia equi [6] , an organism closely related to A. phagocytophila. In a recent serosurvey of residents of Connecticut or Rhode Island, testing for B. burgdorferi was performed by ELISA and Western blot, and testing for A. phagocytophila was performed by ELISA (with a recombinant HGE-44 protein) [7] . In that study, 2 (4%) of 52 patients who had positive IgG responses to B. burgdorferi also had positive IgG responses to A. phagocytophila, and 7 (21%) of 34 persons who had positive IgM responses to B. burgdorferi also had positive IgM responses to A. phagocytophila. However, serological methods may not distinguish between coinfection and sequential infection. More importantly, serological testing may not be completely specific. For example, a positive IgM response to A. phagocytophila may cause a false-positive IgM response to B. burgdorferi [13] .
More recently, prospective studies have been completed in which patients with erythema migrans or acute febrile illness were tested for coinfection by microscopic examination of blood smears, PCR analysis of blood samples, and serological testing. Of 240 patients with Lyme disease on Block Island, Rhode Island, 26 (11%) also had evidence of babesiosis [3] . Of 94 patients with erythema migrans in Wisconsin, 11 (12%) had coinfection with the agent of human granulocytic ehrlichiosis [8] . Finally, in a study of 192 patients with Lyme disease, babesiosis, or anaplasmosis on Block Island, Nantucket Island, Massachusetts, or southeastern Connecticut, 75 (39%) had evidence of coinfection, which occurred most commonly in patients with Lyme disease and babesiosis [4] . The study by Kraus et al. [4] , in particular, suggested that Lyme disease in these areas of endemicity was often accompanied by coinfection.
The yearly incidence of coinfection in our study, which ranged from 0 to 9 cases per 100 patients with erythema migrans, was considerably lower than in previous studies. How does one account for these differences? Methodology is probably a principal factor. Our prospective study examined only patients with culture-proven erythema migrans, and coinfection was documented by PCR or IgG seroconversion. Therefore, the lower incidence of coinfection in our study may be due in part to the rigorous methods used to document active infection with each of the 3 agents studied and, perhaps, to yearly differences in the frequency of coinfected ticks in different geographic locations.
Anaplasmosis or babesiosis often causes only mild or asymptomatic infection. In one serosurvey, 30 (79%) of 38 patients with antibody to B. microti had no symptoms of the infection [3] . However, both anaplasmosis and babesiosis may be more severe in older people [4] , and in very young, older, or asplenic individuals, B. microti may result in a severe, malaria-like illness [14] . When patients are coinfected with B. burgdorferi and B. microti and/or A. phagocytophila, they may have a greater array of nonspecific symptoms; in particular, fever, chills, headache, and especially fatigue (which may persist longer) [15] . Consistent with these observations, the clinical pictures of 3 of our 4 coinfected patients included a large number of symptoms, and 1 coinfected patient had persistent fatigue after treatment.
However, the small number of coinfected patients made statistical comparisons with B. burgdorferi-infected patients meaningless. Overall, the impact of coinfection in our patients with erythema migrans seemed small.
In summary, the frequency of coinfection among patients in the current study was low. Nevertheless, it is important for physicians to be aware of the possibility of coinfection in patients with erythema migrans, because in certain cases, these coinfecting agents may cause severe or even life-threatening illness.
